WP4 - Improved accessibility through supply chains and economic models
Aim: To investigate which factors affect the accessibility of important antibiotics in Sweden, and to identify innovative strategies and business models to improve accessibility.
With expertise from Linköping University, the University of Gothenburg, Uppsala University, the Swedish Association of the Pharmaceutical Industry, the Swedish Pharmaceutical Society, and the companies Pfizer, Mylan, Recipharm and MSD, WP4 identifies all factors that affect the accessibility of antibiotics in Sweden and investigate selected supply chains with focus on eg. lack of profitability, poor environmental and social sustainability, natural disaster and political risk. This WP will recommend measures for improved accessibility of antibiotics in the form of new financial incentives to suppliers, as well as purchasing strategies and logistics processes for healthcare.